Efficacy and Safety of Rifaximin in Treating MAFLD
NCT07185932
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Metabolic-associated Fatty Liver Disease
Interventions
DRUG:
Rifaximin (Xifaxan)
Sponsor
Shanghai Changzheng Hospital